CLBT vs CORZ
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CLBT · Cellebrite$12.45 ▲ 0.57%
CORZ · Core Scientific$11.76 ▲ 3.34%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CLBT -20.2%
- CORZ -39.0%
Head to head
| Metric | CLBT | CORZ |
|---|---|---|
| Price | $12.45 | $11.76 |
| Change today | ▲ 0.57% | ▲ 3.34% |
| Market cap | $3.13B | $3.79B |
| Return, 3 months | -21.7% | -39.5% |
| Return, year to date | -30.9% | -19.2% |
| Return, 1 year | -19.2% | -41.8% |
| P/E (TTM) | 54.1 | – |
| P/B | 5.8 | -3.5 |
| P/E percentile vs own 5y | 94th | 78th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +15.8% | +108.8% |
| Net profit growth (YoY) | -67.3% | -23.3% |
| Gross margin | 83.0% | 28.3% |
| Operating margin | 10.9% | -45.8% |
| Net margin | 11.3% | -372.6% |
| Return on equity | 12.3% | – |
| Analyst target vs. price | +17.5% | +170.2% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 62 | 38 |
| 30-day volatility | 32.3% | 93.0% |
| Max drawdown, 1 year | -45.9% | -61.0% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CORZ is the largest of the group by market value.
- CLBT has returned the most over the past year.
- CORZ is growing revenue fastest.
- CLBT keeps the most profit per dollar of sales.
- CLBT has been the calmest stock over the last 30 days.